16th World ADC San Diego 2025
After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, important questions are being raised about how many ADCs will lead to significant patient impact in such crowded payload MoA and target landscapes.
One thing is clear: as ADCs strive to become earlier-line oncology treatments, the need for innovation has never been more important. Returning as the world’s largest and longest-standing ADC-dedicated forum, the 16th World ADC San Diego is THE week to fully immerse yourself in all things antibody-drug conjugate, spotlighting the cutting-edge innovation empowering the industry to develop differentiated ADCs that show clear advantages against standard of care therapies with clinically meaningful patient benefit.
With 7 streams of end-to-end content, spanning discovery chemistry, discovery biology, preclinical, translational medicine, clinical lessons, process and analytical development, and manufacturing and supply chain, this is your one-stop ADC shop to bring yourself up to speed with the fundamentals, including:
- Advancing Beyond Copycat Conjugates: Gain fresh insights into novel cytotoxic and non-cytotoxic payload mechanisms, emerging dual payload performance, and improved ADC tumor targeting to combat patient resistance with AstraZeneca, Byondis, and Genentech
- Overcoming the ADC Translational Mismatch: Explore detailed case studies on designing ADCs with better tolerability, learn best practices to predict clinical activity, and understand methods to mitigate patient toxicities to successfully progress your ADC into and through the clinic AbbVie, Shasqi, and SOTIO Biotech
- Achieving ADC Clinical Differentiation: Strengthen your clinical strategy by leveraging technologies for optimal patient selection, smartly select the correct combination partners, and demonstrate differentiation in crowded clinical landscapes with Daiichi Sankyo, GSK, and Pfizer
- Reducing ADC Production Costs: Streamline process development with site-specific conjugation, scale-up to late-stage manufacturing with confidence, and ensure sustainable, cost-efficient development to make ADCs more accessible to patients with BeOne Medicines, Exelixis, and Merck & Co.
Download the Full Event Guide here to learn more.
Providing unparalleled networking opportunities with over 1,400 attendees across start-ups, experienced biotechs, large pharma, and leading service providers: anybody who is anybody in the ADC field will unite under one roof to harness ADC innovation and success to provide long-term benefit to patients.
Don’t miss out on your exclusive chance to learn, find new benchmarks, or facilitate new partnerships in this blooming field.
